E 3710

Drug Profile

E 3710

Alternative Names: E-3710; Z 215

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; SFJ Pharmaceuticals; Zeria
  • Class Antiulcers; Gastric antisecretories
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Erosive oesophagitis; Gastro-oesophageal reflux

Most Recent Events

  • 18 Oct 2016 Phase-II clinical trials in Gastro-oesophageal reflux in USA (PO) (SFJ Pharmaceuticals pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux(In volunteers) in USA (PO)
  • 03 Dec 2015 Zeria Pharmaceutical plans a phase I mass balance and pharmacokinetics trial in Healthy volunteers in United Kingdom (PO) (NCT02618629)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top